STAT3 and hepatocellular carcinoma: To further determine the role of STAT3 inhibition in the anti-HCC effects of EEAC, HepG2 cells were transiently transfected with constitutively active STAT3 (STAT3C) plasmid for 48 h, and then treated with EEAC for 24 h.